Open AccessCoagulation Factor IX for Hemophilia B Therapy
Author(s) -
Nadezhda Orlova,
С. В. Ковнир,
I. I. Vorobiev,
А. Г. Габибов
Publication year - 2012
Publication title -
acta naturae
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 26
ISSN - 2075-8251
DOI - 10.32607/actanaturae.10645
Subject(s) - factor ix , zymogen , genetic enhancement , coagulation , recombinant dna , medicine , coagulation cascade , enzyme replacement therapy , immunology , gene , enzyme , biology , genetics , thrombin , platelet , biochemistry , disease
Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy. Reviewed herein are the current state in the manufacturing of FIX, improved variants of the recombinant protein for therapy, transgenic organisms for obtaining FIX, and the advances in the gene therapy of hemophilia B.